While lipid-lowering drugs to combat hypercholesterolemia are indispensable in treating and reducing cardiovascular disease risk, evidence from trials suggests that the fundamental role of the inflammatory marker CRP should be acknowledged and employed to assess cardiovascular risk, in addition to the residual risk in patients with CVD (Figure 7). Here, CRP is linked to cardiovascular disorder.